Medicare billing address
CMS Medicare provider billing file
222 E Mcmurray RdMc Murray, PA 15317
CMS public data · NPI 1912907452
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Mark P Seraly, M.D.
Specialty
Credential
M.D.
NPI
1912907452
Primary source state
PA
Data retrieval date
July 28, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Mark P Seraly, M.D. from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
222 E Mcmurray RdCMS Doctors & Clinicians file
222 E Mcmurray RdIn the 2024 CMS provider billing file, this NPI had 946 Medicare beneficiaries and 34,460 total services. The average beneficiary age was 74, and the average HCC risk score was 0.9.
Total Medicare allowed amount
$593,445.08
Total Medicare payment amount
$451,695.68
Medicare beneficiaries
946
Total services
34,460
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
67%
CMS beneficiary-panel share
Ischemic heart disease
24%
CMS beneficiary-panel share
Anxiety
22%
CMS beneficiary-panel share
Diabetes
21%
CMS beneficiary-panel share
Chronic kidney disease
17%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 29,800 | $1.67 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 855 | $89.63 |
| Ultrasonic guidance for placement of radiation therapy fields | 500 | $174.08 |
| Obtaining data needed to develop the optimal radiation treatment, 1 treatment area | 486 | $260.06 |
| Superficial and/or low voltage radiation treatment delivery | 464 | $39.96 |
| Destruction of precancer skin growth, 2-14 growths | 405 | $6.39 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 331 | $126.27 |
| Destruction of precancer skin growth, 1 growth | 259 | $59.78 |
| Application of light with debridement to destroy precancer skin growth | 161 | $266.39 |
| Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more | 139 | $55.64 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1912907452. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Triamcinolone Acetonide | Triamcinolone Acetonide | 192 | 207.6 | $2,304.65 |
| 2 | Clobetasol Propionate | Clobetasol Propionate | 188 | 199 | $10,884.54 |
| 3 | Doxycycline Hyclate | Doxycycline Hyclate | 130 | 154.2 | $2,336.12 |
| 4 | Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 107 | 109 | $1,900.56 |
| 5 | Minoxidil | Minoxidil | 99 | 210 | $366.18 |
| 6 | Imiquimod | Imiquimod | 98 | 151.6 | $2,509.66 |
| 7 | Ketoconazole | Ketoconazole | 89 | 91 | $886.45 |
| 8 | Fluorouracil | Fluorouracil | 76 | 76.4 | $5,269.39 |
| 9 | Ciclopirox | Ciclopirox | 65 | 79.9 | $4,030.40 |
| 10 | Clindamycin Phosphate | Clindamycin Phosphate | 60 | 61 | $2,266.43 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Medical school
Jefferson Medical College Of Thomas Jefferson University
Graduation year
1990
Group/practice field
Mark P. Seraly, Md, Pc
Telehealth reported
Not reported
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.